Advanced searches left 3/3

Metastatic Non-Small Cell Lung Cancer - Crossref

Summarized by Plex Scholar
Last Updated: 27 January 2022

* If you want to update the article please login/register

Gamma knife radiosurgery for metastatic brain tumors from lung cancer: a comparison between small cell and non—small cell carcinoma

Comparing non-SCLC versus non-SCLC, the purpose of this retrospective review was to determine the safety of gamma knife radiosurgery for the treatment of metastatic brain tumors from lung cancer, with particular focus on small cell lung carcinomas. The SCLC group's 1-year survival rates were 86. 5% for neurological and 68. 9% for qualitative survival, with 89 percent for qualitative survival; those in the NSCLC group were 87. 9% for neurological and 78. 9% for qualitative survival; those in the NSCLC group had 86. 9% for demographic survival and 78. 9% for qualitative survival; and 68. 9% for qualitative survival. The results of this report indicate that GKS appears to be equally effective in treating brain metastases from SCLC as well as those from NSCLC.

Source link: https://doi.org/10.3171/jns.2002.97.supplement_5.0484


Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non–small cell lung cancer to the brain: a matched cohort study

OBJECTIVE Immune checkpoint inhibitors improve survival in patients with advanced non-small cell lung cancer (ALS). Patients with NSCLC with ICIs were excluded from the clinical trials examining the efficacy of ICIs in patients with NSCLC, as well as patients with untreated brain metastases. The authors sought to establish the safety and radiological and clinical results for patients with NSCLC-BMs treated with concurrent ICI and SRS as stereotactic radiosurgery is commonly employed for NSCLC-BMs. METHODS The study was performed as a retrospective matched cohort study was conducted on patients who had undergone SRS for one or two NSCLC-derived BMs. In the same vein, the 12-month local tumor control rate in the concurrent-ICI cohort was 89% for tumors, compared to 76. 3% for tumors in the ICI-naive cohort. Patients receiving concurrent ICI had an elevated risk of CNS complete response for BMs treated with SRS as per the Response Assessment in Neuro-Oncology guidelines, according to a new study.

Source link: https://doi.org/10.3171/2019.4.jns19822

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions